Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EWTX 
Edgewise Therapeutics Inc (EWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: EWTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.15
1 Year Target Price $36.15
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.51% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.59B USD | Price to earnings Ratio - | 1Y Target Price 36.15 |
Price to earnings Ratio - | 1Y Target Price 36.15 | ||
Volume (30-day avg) 10 | Beta 0.29 | 52 Weeks Range 10.60 - 38.12 | Updated Date 10/14/2025 |
52 Weeks Range 10.60 - 38.12 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.06% | Return on Equity (TTM) -27.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 990564620 | Price to Sales(TTM) - |
Enterprise Value 990564620 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.6 | Shares Outstanding 105345708 | Shares Floating 60532697 |
Shares Outstanding 105345708 | Shares Floating 60532697 | ||
Percent Insiders 0.44 | Percent Institutions 113.68 |
Upturn AI SWOT
Edgewise Therapeutics Inc
Company Overview
History and Background
Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for severe genetic muscle disorders. Founded in 2017, the company has advanced rapidly through preclinical and clinical development, with its lead candidate targeting Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
Core Business Areas
- Drug Development: Focused on discovering, developing, and commercializing novel therapies for genetic muscle disorders.
Leadership and Structure
The company is led by CEO Kevin Koch, PhD, and has a management team with experience in drug development and commercialization. They operate with a standard pharmaceutical company structure, including research, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- EDG-5506: EDG-5506 is an orally administered small molecule designed to reduce muscle damage in DMD and BMD patients by selectively addressing muscle fiber instability. It's currently in Phase 2 clinical trials. Competitors include Sarepta Therapeutics and Pfizer, which have gene therapies and exon-skipping drugs for DMD. Market share is not yet available as the drug is pre-market launch.
Market Dynamics
Industry Overview
The industry is characterized by high unmet need for effective treatments for genetic muscle disorders. Focus on rare diseases allows for government benefits.
Positioning
Edgewise is positioned as a developer of small molecule therapies, offering a potential alternative to gene therapies and other approaches. This positions them well for patients looking for oral delivery methods.
Total Addressable Market (TAM)
The TAM for DMD and BMD is estimated to be in the billions of dollars, with a substantial portion still unaddressed by current therapies. Edgewise aims to capture a significant market share with EDG-5506.
Upturn SWOT Analysis
Strengths
- Novel small molecule approach
- Potential oral delivery advantage
- Experienced management team
- Focus on underserved market
Weaknesses
- Single clinical-stage asset
- High cash burn rate
- Relatively young company
- Reliance on clinical trial success
Opportunities
- Expansion into other genetic muscle disorders
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results driving valuation
- Orphan drug designation benefits
Threats
- Clinical trial failure
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Financing risk
Competitors and Market Share
Key Competitors
- SRPT
- PFE
- PTCT
Competitive Landscape
Edgewise has a unique approach as a small-molecule. Sarepta has exon-skipping treatments and gene therapy. PTC also has exon skipping drugs.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the advancement of EDG-5506 through clinical trials.
Future Projections: Future growth depends on the success of clinical trials and potential regulatory approvals. Analyst estimates vary widely, reflecting the inherent risks in drug development.
Recent Initiatives: Recent initiatives include expanding clinical trials for EDG-5506 and exploring potential partnerships.
Summary
Edgewise Therapeutics is a high-risk, high-reward biopharmaceutical company focused on genetic muscle disorders. The company's future hinges on the success of its lead candidate, EDG-5506. While their small-molecule approach provides a potential advantage, they face competition from larger, established players. The company's high cash burn rate necessitates careful financial management, and positive clinical trial data are essential to maintain investor confidence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Edgewise Therapeutics Inc. SEC Filings (e.g., 10-K, 10-Q)
- Company website and press releases
- Analyst reports (e.g., from major investment banks)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edgewise Therapeutics Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2021-03-26 | President, CEO & Director Dr. Kevin Koch Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 126 | Website https://edgewisetx.com |
Full time employees 126 | Website https://edgewisetx.com | ||
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.